Pricing Log in Create free account

Actuate Therapeutics, Inc. (ACTU) vs BioLineRx Ltd. (BLRX)

Actuate Therapeutics, Inc. and BioLineRx Ltd. are both Biotechnology companies. Actuate Therapeutics, Inc. is the larger, with a market value of $18.0M against $8.8M — 2.0× the size. Actuate Therapeutics, Inc. has the higher net margin (0.00% vs −502.1%) and the higher return on invested capital (0.00% vs −74.3%). Across the 13 metrics below, Actuate Therapeutics, Inc. leads on 8 and BioLineRx Ltd. on 5.

Valuation

Metric ACTU BLRX Biotechnology median
P/E n/m n/m 10.26
P/S n/m 5.65 9.18
P/B 8.21 0.47 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 1.06 8.98
Earnings yield (255.88%) (90.47%) (34.89%)
Free cash flow yield (244.40%) (137.86%) (24.52%)

Profitability

Metric ACTU BLRX Biotechnology median
Gross margin — 80.03% 65.16%
Operating margin 0.00% (874.28%) 0.00%
Net margin 0.00% (502.08%) 0.00%
Free cash flow margin 0.00% (776.29%) 0.00%
Return on equity 2,457.65% (38.10%) (50.12%)
Return on assets (336.18%) (18.21%) (45.60%)
Return on invested capital 0.00% (74.28%) 0.00%

Growth

Metric ACTU BLRX Biotechnology median
Revenue growth (TTM) — (91.93%) 6.26%
EPS growth (last fiscal year) 67.48% 93.72% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ACTU BLRX Biotechnology median
Debt to equity 0.00 0.40 0.00
Current ratio 1.25 1.20 4.89
Net debt to EBITDA 0.59 1.22 1.01

Dividend

Metric ACTU BLRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACTU BLRX Biotechnology median
Market cap 17.98m 8.80m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack